WASHINGTON, May 13, 2026 /PRNewswire/ -- A new awareness campaign, This is ALZ, launched today to challenge long-held perceptions of Alzheimer's by revealing what the disease looks like in its earlier ...

NEW YORK, April 2, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative treatments for unmet medical needs, today announced ...

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Alzheon, Inc., a clinical-stage biopharmaceutical company developing a broad portfolio of investigational therapies and diagnostic assays for patients with ...

ALZ-NET is the first network developed specifically for new FDA-approved Alzheimer's treatments, collecting real-world evidence on drug effectiveness and side effects over a long period of time. The ...

SAN DIEGO, Aug. 1, 2022 /PRNewswire/ -- The Alzheimer's Association announces that the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) — a new platform that will collect long-term clinical ...

Please provide your email address to receive an email when new articles are posted on . The Alzheimer’s Association is among a group of professional societies and research institutions that have ...

There are multiple different types of drugs available for the treatment of Alzheimer’s disease: cholinesterase inhibitors to treat symptoms from mild to severe, and disease-modifying immunotherapies ...

Alzinova is at an important stage of development. The global Phase II study of ALZ-101 is in operational start-up together with Worldwide Clinical Trials, with the aim of enrollin ...

Alzheon Advances Industry-Leading Portfolio of Oral Anti-Amyloid Aggregation Inhibitors with First Subject Dosed in Phase 1 of ALZ-507, Highlighting Potential for Once-Daily Administration, Improved ...

Alzinova AB announced that CEO Tord Labuda will present the Company at Redeye Neurology Day on October 15, 2026. The presentation will focus on Alzinova?s continued development in the treatment and ...